Sting crystals and modulators
US-2016210400-A1 · Jul 21, 2016 · US
Compositions and methods for activating stimulator of interferon gene-dependent signalling
US9724408B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9724408-B2 |
| Application number | US-201414280667-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 18, 2014 |
| Priority date | May 18, 2013 |
| Publication date | Aug 8, 2017 |
| Grant date | Aug 8, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2′,5′,2′,5′ and 2′,5′,3′,5′ CDNs, and preferably Rp,Rp stereoisomers thereof.
First claim
Opening claim text (preview).
We claim: 1. A compound of the formula where R 1 and R 2 are each H, or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition: a compound according to claim 1 formulated with a pharmaceutically acceptable carrier. 3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical acceptable carrier comprises one or more agents selected from the group consisting of lipids, interbilayer crosslinked multilamellar vesicles, biodegradeable poly(D,L-lactic-co-glycolic acid) [PLGA]-based or poly anhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers. 4. A composition comprising: a compound according to claim 1 and one or more antigens selected for purposes of inducing an immune response against the antigen(s) when the composition is administered to an individual. 5. A method of inducing stimulator of interferon genes protein (STING)-dependent type I interferon production in an individual in need thereof, comprising: administering a compound according to claim 1 to the individual in an amount sufficient to induce STING-dependent type I interferon production. 6. The method according to claim 5 , wherein the administration is directly into a tumor mass.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9724408B2 cover?
- The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon productio…
- Who is the assignee on this patent?
- Aduro Biotech Inc, Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).